Narechania Shraddha, Torbic Heather, Tonelli Adriano R
Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA.
Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA.
J Cardiovasc Pharmacol Ther. 2020 Mar;25(2):131-141. doi: 10.1177/1074248419877409. Epub 2019 Oct 8.
Pulmonary arterial hypertension (PAH) is a progressive disease, which can be potentially fatal. The management of a complex disease like PAH requires a multidisciplinary approach from a team consisting of physicians, nurses, social workers, and pharmacists. Adherence to PAH-specific therapy is one of the key factors in the management of this disease. Poor adherence to treatment is a common problem in PAH as it is in many chronic diseases. Management of medication interruptions is a challenge in patients with PAH that can lead to negative consequences. However, for most PAH-specific drugs, there are no clear guidelines on how to manage temporary or abrupt medication discontinuations. In this review, we summarized the available literature and provide suggestions on how to manage interruptions of PAH-specific therapies.
肺动脉高压(PAH)是一种进行性疾病,可能会致命。像PAH这样的复杂疾病的管理需要由医生、护士、社会工作者和药剂师组成的团队采取多学科方法。坚持PAH特异性治疗是该疾病管理的关键因素之一。与许多慢性疾病一样,PAH患者中治疗依从性差是一个常见问题。药物中断的管理对PAH患者来说是一项挑战,可能会导致负面后果。然而,对于大多数PAH特异性药物,关于如何管理临时或突然停药并没有明确的指南。在本综述中,我们总结了现有文献,并就如何管理PAH特异性治疗的中断提供建议。